Premium
Idelalisib in relapsed/refractory diffuse large B‐cell lymphoma: results from a Nordic Lymphoma Group phase II trial
Author(s) -
Fjordén Karin,
Ekberg Sara,
Kuric Nevzeta,
Smedby Karin E.,
Lagerlöf Ingemar,
Larsen Thomas S.,
Jørgensen Judit M.,
Nully Brown Peter,
Jerkeman Mats
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17792
Subject(s) - idelalisib , ibrutinib , diffuse large b cell lymphoma , bruton's tyrosine kinase , oncology , medicine , lymphoma , cancer research , chronic lymphocytic leukemia , leukemia , tyrosine kinase , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom